Author(year) | Case | Age | Genotype (N) | Microsatellite instability status | PD-L1 expression | Intervention methods | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
WT | BRAF MU | KRAS MU | Unknown |  ≥ 1% |  < 1% | Unknown | |||||
Overman (2018) | 119 | 58(21–88) | 31 | 29 | 44 | 15 | MSI–H 119 | 26 | 65 | 28 | Nivolumab (PD-1)  + Ipilimumab (CTLA-4) |
Overman (2017) | 74 | 53(44–66) | 29 | 12 | 26 | 7 | MSI–H 74 | 21 | 47 | 6 | Nivolumab (PD-1) |
Le D T (2019) | 124 | 56(21–84) | 17 | 14 | 46 | – | MSI–H 124 | – | – | – | Pembrolizumab (PD-1) |
O’Neil (2017) | 23 | 57(40–78) | – | – | – | – | MSI–H 1 MSS 22 | 23 | – | – | Pembrolizumab (PD-1) |
Le D T (2015) | 32 | 54(24–79) | – | 19 | 19 | – | MSI–H 11 MSS 21 | – | – | – | Pembrolizumab (PD-1) |
André T (2020) | 307 | 63(24–93) | 69 | 77 | 74 | 90 | MSI–H 307 | – | – | – | Pembrolizumab (PD-1) |
Fukuoka (2020) | 25 | 55(31–77) | – | – | 6 | – | MSI–H 3 MSS 22 | 9 | 16 | – | Nivolumab (PD-1)  + Regorafenib |
Herting (2020) | 30 | 49(28–74) | 21 | 0 | 14 | 26 | MSI–H 2 MSS 9 Unknown 19 | – | – | – | Pembrolizumab (PD-1)  + Modified FOLFOX6 |
Kawazoe (2020) | 50 | 58(25–79) | 4 | 28 | 19 | 13 | MSI–H 10 MSS 40 | 4 | – | – | Pembrolizumab (PD-1)  + Napabucasin" |
Eng C (2019) A | 183 | 58 (51–67) | 258 | 9 | 99 | – | MSI–H 3 MSS 170 Unknown 10 | 79 | 84 | 20 | Atezolizumab(PD-L1)  + Cobimetinib |
Eng C (2019) B | 90 | 56 (51–64) | 128 | 3 | 49 | – | MSI–H 3 MSS 83 Unknown 4 | 35 | 42 | 13 | Atezolizumab(PD-L1) |
Hellmann (2019) | 84 | 56(23–79) | 63 | 40 | 24 | 41 | MSI–H 2 MSS 61 Unknown 21 | – | – | – | Atezolizumab(PD-L1)  + Cobimetinib |
Patel (2021) | 18 | 56(40–70) | – | 1 | 12 | – | MSS 18 | – | – | – | Nivolumab(PD-1)  + Rifluridine/Tipitaka (FTD/TPI) |
Cousin (2021) | 48 | 62 (26–83) | – | 3 | 30 | – | MSS 48 | 6 | – | – | Aveluma (PD-L1)  + Regorafenib |
Chen (2020) | 180 | 65 (36–87) | – | – | – | – | MSI–H 2 MSS 166 Unknown 12 | – | – | – | Durvalumab(PD-L1) +  Tremelimumab(CTLA-4) |
Martinelli (2021) | 77 | – | 48 | 19 | 19 | 3 | MSI–H 3 MSS 71 Unknown 4 | – | – | – | Avelumab(PD-L1)  + cetuximab |
Wang (2021) | 39 | 52(37–69) | 13 | 2 | 20 | 4 | MSS 38 MSI–L 1 | – | – | – | Toripalimab(PD-1)  + regorafenib |